Skip to main content

Plaintiff Seeks To Revive Zimmer Hip Implant Lawsuit

Plaintiff Seeks To Revive Zimmer Hip Implant Lawsuit

Plaintiff Seeks To Revive Zimmer Hip Implant Lawsuit

Introduction

In a September 10 notice of appeal, a plaintiff involved in the Zimmer hip implant litigation has appealed to the 3rd Circuit U.S. Court of Appeals to reinstate her lawsuit, which was dismissed last month by U.S. District Court Judge Edward G. Smith over late filing.

The plaintiff was implanted with Zimmer Inc.’s Kinectiv Technology hip implant system with a VerSys femoral head in 2011. She experienced metallosis, an adverse tissue reaction, allegedly due to the design defects of the hip implant and eventually removed it in 2015. She sued the manufacturer in February 2017 accusing them of failing to provide adequate warning. However, the New Jersey jury rejected her claims as she had crossed the two-year statute of the limitation period.

Zimmer Durom Hip Cup multidistrict litigation was centralized on June 9, 2010, in the U.S District of New Jersey before Judge Susan D. Wigenton as multidistrict litigation, MDL No. 2158 (In Re: Zimmer Durom Hip Cup Products Liability Litigation).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.